Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission

Steven E. McCormack, Qing Cao, Betul Oran, Daniel J. Weisdorf, Erica D. Warlick

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

The role consolidation chemotherapy prior to reduced-intensity (RIC) HCT is unclear. We reviewed 60 consecutive patients with AML in CR1 undergoing RIC HCT at the University of Minnesota and evaluated outcomes based on exposure to pre-transplant consolidation chemotherapy. The two year incidence of relapse and the probability of overall survival were similar between those who did and did not receive consolidation chemotherapy. The 2 year incidence of transplant-related mortality was slightly higher in those who did not receive consolidation and correlated with a higher HCT comorbidity index (HCT-CI) in that cohort. Our data suggest that exposure to consolidation chemotherapy prior to RIC HCT may not improve post-transplant outcomes for patients with AML in CR1.

Original languageEnglish (US)
Pages (from-to)757-761
Number of pages5
JournalLeukemia research
Volume35
Issue number6
DOIs
StatePublished - Jun 1 2011

Keywords

  • AML
  • Allogeneic stem cell transplantation
  • CR1
  • Consolidation therapy
  • Reduced-intensity conditioning

Fingerprint Dive into the research topics of 'Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission'. Together they form a unique fingerprint.

  • Cite this